Joaquin Gomez of Ingeniatrics discusses their Flow Focusing and Flow Blurring technology




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Joaquin Gomez of Ingeniatrics discusses their Flow Focusing and Flow Blurring technology
Released on: March 23, 2011. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Fintan Walton talks to Joaquin Gomez, CEO at Ingeniatrics
Technology and Application areas
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here from BioPharm America in Boston. On this show I have Joaquin Gomez Moya , who is CEO of a company called Ingeniatrics , which is based in Seville, in Spain, welcome to the show.
Joaquin Gomez Moya:
Good morning.
Fintan Walton:
Good morning to you. Tell me little bit about your company and the technology it has.
Joaquin Gomez Moya:
Well, Ingeniatrics was founded by Alfonso Ganan-Calvo who was the discoverer of Flow-Focusing phenomenon, first discoverer the axisymmetrical Flow-Focusing for those formula with the microfluidics. Alfonso Ganan-Calvo is a full professor in the University of Seville, then he thought that he could make Ingeniatrics to market solutions applying this technology Flow-Focusing and all the microfluidics phenomenon with similar mathematical, geometrical configuration Flow-Blurring, ElectroFlow-Focusing, ConcentricFlow-Focusing.
Fintan Walton:
Right, so that was the that's the basis of the company that capability, that technology that's embedded in the company, so how do you apply that into the pharmaceutical industry?
Joaquin Gomez Moya:
Okay, Flow-Focusing allows us to produce micro particles from less then one micron to several hundred of micron, so with a smoothness not all the technology can provide with a control of size and versatility regarding their materials or (indiscernable) involvement that it is very hard to find in any other technology to produce micro-encapsulation. So we thought that our focus should be pharma, because this is the field where our technology could provide the final client which is the patient with the product with biggest value added, okay. For an instance we can micro-encapsulate one molecule to add a depot effect or to facilitate their absorption through their stomach or through their skin to add some properties the molecule itself has not, okay.
Fintan Walton:
Yeah, okay. So yes, so in a sense what you are doing is if you got a pharmaceutical active you can enhance the properties of that pharmaceutical active through the generation of different size molecules which can then be formulated into encapsulated, micro-encapsulated so that can be applied to drugs that go into the stomach as you described or it could be a dermatological, but also I assume that some of that technology can be used for inhalation as well is that another application?
Joaquin Gomez Moya:
Yes right, rightly so. Thus such a wide field of application we couldn't update it in a short interview because the ground opened before us with this technology is incredibly incredibly wide, but we can also study sales or affected by concept for instance or microorganism making the encapsulation so with these technologies allowing us to produce (indiscernable) firstnot touching the orifice the hole through they come out we can study populations of different cancer or their ecosystems creating micro ecosystems we can as we control disease we can compare the evaluation of these mixed fares one or of other and we are collaborating with some universities in the utilization of our technology combining with flow cytometry for instance now.
Collaborations and funding
Fintan Walton:
Right, so with this it is very important with that basic technology that very important technology collaboration becomes an important part of that, so collaboration with other universities, collaborations with other pharmaceutical companies, so how is that working for you at the moment, how are those collaborations working?
Joaquin Gomez Moya:
Well, so far we have been collaborating with the universities and big corporates and International corporates to make proof of concept to apply with different substances in different matrices to different aims our technology and from now on we have started to manufacture the microencapsulates not only we are providing the research services, but as well we are able to produce the microencapsulate.
Fintan Walton:
Okay, so you have a not , it's not just at the lab it's now you have the capability of manufacturing micro-encapsulation?
Joaquin Gomez Moya:
Molecule substances or whatever.
Fintan Walton:
Right, very interesting. So at the moment the company is backed by venture capital is it got private money behind it or how is it, how is your company funded?
Joaquin Gomez Moya:
At this moment we are about to complete a round with several investors with mainly typical venture capital funds, but it is a publically held company. Alfonso Ganan-Calvo and some several other companions mainly as they were teachers in the university budding entrepreneurs which is a not frequently often found in Spain, but now we are needing more funds and so we are in talks with several funds and advanced conversation.
Participation at BioPharm America
Fintan Walton:
Good, well and then now you are here in Boston you are attending BioPharm America, what do you hope to get from this meeting?
Joaquin Gomez Moya:
Okay, I have recently entered the company six months ago, so I was much interested in visiting the main places and then my scientists told me well first of all you should go to Massachusetts because there lies the main cluster in the world our competitors so to say competitors, but may be they are competitors in the future may be they are collaborators, well lets see. I had to be here to see what we can afford, what our potential customers are molting that is on and what we can do in the future.
Fintan Walton:
Joaquin Gomez Moya , thank you very much for coming on the show.
Joaquin Gomez Moya:
Thanks to you.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Joaquin Gomez Moya
Chief Executive Officer
Joaquin Gomez Moya currently holds the position of CEO at Ingeniatrics Tecnologias , COO / Director de Operaciones at Ingeniatrics Global LLC, Voting Trustee Observer at Ingeniatrics . In the past Joaquin Gomez Moya had served as General Manager Director General at Vinispana, University lecturer at UCLM, Managing Director Director Gerente at Invencible, Sales Account. Joaquin Gomez Moya completed his education from University of Cambridge, ESDEN, Escuela de Organizaci"n Industrial, IEDE Institute for Executive Development and Universidad Nacional de Educacion.
PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
Ingeniatrics Tecnologias
Ingeniatrics Tecnologias is a privately owned technology-based company (TBC), created in 2001 by a team of biotech entrepreneurs and researchers from the University of Seville. Ingeniatrics born in response to the idea of developing a vehicle to implement diverse applications of Technology Platform that comprises a bundle of technologies allows the differential handling of a wide variety of fluids. Ingeniatrics Tecnologias is a technology-based company (TBC) with over 50 patents and applications nationally and internationally, in Flow-Focusing and Flow-Blurring micro and nanoscale production technologies of aerosols, particles, emulsions and microencapsulation. Ingeniatrics Tecnologias mission is to offer technically innovative products and services, with high added value and sustainability like OneNeb, Frialia, Cell-ENA, Flow-Focusing microencapsulation services. Our vision focuses on maximizing and implementing our expertise in microfluidic technologies.